RUA Life Sciences plc
RUA.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | £4,113 | £2,191 | £2,179 | £1,625 |
| % Growth | 87.7% | 0.6% | 34.1% | – |
| Cost of Goods Sold | £941 | £475 | £746 | £580 |
| Gross Profit | £3,172 | £1,716 | £1,433 | £1,045 |
| % Margin | 77.1% | 78.3% | 65.8% | 64.3% |
| R&D Expenses | £0 | £887 | £1,086 | £928 |
| G&A Expenses | £4,161 | £1,148 | £1,092 | £1,320 |
| SG&A Expenses | £4,161 | £2,479 | £2,609 | £2,175 |
| Sales & Mktg Exp. | £0 | £13 | £23 | £9 |
| Other Operating Expenses | -£969 | £34 | £128 | £371 |
| Operating Expenses | £3,192 | £3,400 | £3,823 | £3,474 |
| Operating Income | -£989 | -£1,937 | -£2,306 | -£2,352 |
| % Margin | -24% | -88.4% | -105.8% | -144.7% |
| Other Income/Exp. Net | £979 | -£83 | -£16 | -£8 |
| Pre-Tax Income | -£10 | -£2,020 | -£2,322 | -£2,360 |
| Tax Expense | £11 | -£580 | -£319 | -£293 |
| Net Income | £1 | -£1,440 | -£2,003 | -£2,067 |
| % Margin | 0% | -65.7% | -91.9% | -127.2% |
| EPS | 0 | -0.043 | -0.09 | -0.093 |
| % Growth | 100% | 52.5% | 3.1% | – |
| EPS Diluted | 0 | -0.043 | -0.09 | -0.093 |
| Weighted Avg Shares Out | 62,500 | 33,566 | 22,185 | 22,185 |
| Weighted Avg Shares Out Dil | 62,060 | 33,566 | 22,185 | 22,185 |
| Supplemental Information | – | – | – | – |
| Interest Income | £10 | £0 | £0 | £0 |
| Interest Expense | £0 | £83 | £16 | £8 |
| Depreciation & Amortization | £421 | £364 | £358 | £313 |
| EBITDA | £401 | -£1,573 | -£1,948 | -£2,039 |
| % Margin | 9.7% | -71.8% | -89.4% | -125.5% |